Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
0.5 (1y: -74%)
Market Cap 51.2 M P/E(ttm)
Enterprise Value 49.99 M P/B 1.39
CMXI- OTCBB (USA)
Cytomedix, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$0.50
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry		 vs
history
Cash to Debt 1.271
CMXI's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: 1.271 )
CMXI' s 10-Year Cash to Debt Range
Min: 0.2   Max: No Debt
Current: 1.27
Equity to Asset 0.062
CMXI's Equity to Asset is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: 0.062 )
CMXI' s 10-Year Equity to Asset Range
Min: -8.63   Max: 0.66
Current: 0.06
-8.63
0.66
F-Score: 2
Z-Score: -0.3
M-Score: -2.82
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry		 vs
history
Operating margin (%) -122.10
CMXI's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: -122.10 )
CMXI' s 10-Year Operating margin (%) Range
Min: -68755.6   Max: -48.5
Current: -122.1
-68755.6
-48.5
Net-margin (%) -187.4
CMXI's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: -187.4 )
CMXI' s 10-Year Net-margin (%) Range
Min: -68777.8   Max: -48.4
Current: -187.4
-68777.8
-48.4
ROE (%) -52.1
CMXI's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: -52.1 )
CMXI' s 10-Year ROE (%) Range
Min: -3295.8   Max: -26.5
Current: -52.1
-3295.8
-26.5
ROA (%) -44.7
CMXI's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: -44.7 )
CMXI' s 10-Year ROA (%) Range
Min: -2226.6   Max: -22.1
Current: -44.7
-2226.6
-22.1
ROC (Joel Greenblatt) (%) -378.60
CMXI's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: -378.60 )
CMXI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1132.7   Max: -378.6
Current: -378.6
-1132.7
-378.6
Revenue Growth (%) 21.3
CMXI's Revenue Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: 21.3 )
CMXI' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 31.6
Current: 21.3
0
31.6
EBITDA Growth (%) 8.8
CMXI's EBITDA Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: 8.8 )
CMXI' s 10-Year EBITDA Growth (%) Range
Min: -47.4   Max: 8.8
Current: 8.8
-47.4
8.8
EPS Growth (%) 24.5
CMXI's EPS Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: 24.5 )
CMXI' s 10-Year EPS Growth (%) Range
Min: -42   Max: 24.5
Current: 24.5
-42
24.5
» CMXI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with CMXI



No Insider Trades Found!

Ratios

vs
industry		 vs
history
P/B 1.39
CMXI's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: 1.39 )
CMXI' s 10-Year P/B Range
Min: 1.22   Max: 215.6
Current: 1.39
1.22
215.6
P/S 4.55
CMXI's P/S is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: 4.55 )
CMXI' s 10-Year P/S Range
Min: 1.88   Max: 718.67
Current: 4.55
1.88
718.67
EV-to-EBIT -3.29
CMXI's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: -3.29 )
CMXI' s 10-Year EV-to-EBIT Range
Min: 205.8   Max: 284.4
Current: -3.29
205.8
284.4

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 31.9
CMXI's Price/Net Current Asset Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: 31.9 )
CMXI' s 10-Year Price/Net Current Asset Value Range
Min: 19   Max: 1281
Current: 31.9
19
1281
Price/Tangible Book 21.2
CMXI's Price/Tangible Book is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: 21.2 )
CMXI' s 10-Year Price/Tangible Book Range
Min: 1.9   Max: 128.1
Current: 21.2
1.9
128.1
Price/Median PS Value 0.4
CMXI's Price/Median PS Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: 0.4 )
CMXI' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 32.8
Current: 0.4
0.2
32.8
Forward Rate of Return (Yacktman) -31.09
CMXI's Forward Rate of Return (Yacktman) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: -31.09 )
CMXI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -23.2   Max: -20.7
Current: -31.09
-23.2
-20.7

Business Description

Cytomedix, Inc. formerly Informatix Holdings, Inc. was incorporated in Delaware in 1998. In 1999, Autologous Wound Therapy, Inc., an Arkansas Corporation, merged with and into Informatix Holdings, Inc. and the name of the surviving Corporation was changed to Autologous Wound Therapy, Inc. In 2000, AWT changed its name to Cytomedix, Inc. Cytomedix, Inc. develops, sells, and licenses regenerative biological therapies intended to aid the human body in regenerating/healing itself, to primarily address the areas of wound care, infection control, and orthopedic surgery. The Company currently markets the AutoloGelTM System, as well as the Angel Whole Blood Separation System and activAT Autologous Thrombin Processing Kit ("activAT"), both of which were acquired from Sorin USA, Inc. ("Sorin") in April 2010. AutoloGelTM is a device for the production of platelet rich plasma ("PRP") gel derived from the patient's own blood. The AutoloGelTM System is cleared by the Food and Drug Administration ("FDA") for use on a variety of exuding wounds. The Company is currently pursuing a multi-faceted strategy to penetrate the chronic wound market with its AutoloGelTM System. Additionally, the Company has entered into an option agreement with a top 20 global pharmaceutical company granting the potential partner an exclusive option period through June 30, 2012 regarding license of the AutoloGelTM System. Angel and activAT are used primarily in surgical settings. Angel is used for separation of whole blood into red cells, platelet poor plasma and platelet rich plasma. ActivAT is designed to produce autologous thrombin serum from platelet poor plasma and is sold exclusively in Europe and Canada, where it provides a safe alternative to bovine-derived products. The Company is also pursuing opportunities for the application of AutoloGelTM and Angel into other markets such as hair transplantation, pain management, and sports medicine, as well as actively seeking complementary products for regenerative medicine markets. Cytomedix sells its products primarily to health care providers in the United States.
Company Website
SEC Reports
Industry:
Compare:
» More Articles for CMXI

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: SNTA, MEI, PZG, MCHX, CMXI Jul 07 2012 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial